Abstract: The present invention provides for a stable, biologically active CNTF/receptor complex, and hybrids or mutants thereof. The invention is also based in part on the discovery that the CNTF/receptor complex promotes differentiation through a signal transduction pathway on target cells that do not express the CNTF receptor. The invention further provides for a specific CNTFR mutant that promotes signal transduction without binding CNTF. The invention also provides for a CNTF/receptor blocking mutant, a mutant possessing a high binding affinity to CNTF, but possessing no signal transducing function. The present invention also identifies receptor components shared by the IL-6, CNTF, LIF and OSM signal transduction pathways, and the assay systems based on the use of such components.

Abstract: The present invention provides isolated nucleic acid molecules encoding a G-protein coupled receptor that shows homology to the 5HT family of receptors. The present invention further provides vectors containing the nucleic acid molecules, hosts transformed or transfected with the nucleic acid molecules and methods of producing the G-protein coupled receptor.

Abstract: The present invention relates to TKA-1 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for TKA-1 related diseases or conditions characterized by an abnormal interaction between a TKA-1 polypeptide and a TKA-1 binding partner.

Abstract: Crystals of the tyrosine kinase domain of cytoplasmic tyrosine kinases and receptor tyrosine kinases that undergo ligand-mediated receptor dimerization are provided. In particular, crystals of a mutant of the tyrosine kinase domain of fibroblast growth factor receptor 1 (FLGK), alone and in complex with a non-hydrolyzable adenosine triphosphate analogue, are provided. Also provided are the high resolution three dimensional structures of crystalline FLGK, both alone and in co-complex with the adenosine triphosphate analogue, as determined by X-ray diffraction.

Abstract: Human G-protein Coupled receptor HIBEF51 polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the receptor polypeptides, respectively. Also disclosed are diagnostic methods for detecting a mutation in the human G-protein Coupled receptor HIBEF51 nucleic acid sequences and detecting a level of the soluble form of the receptors in a sample derived from a host.

Abstract: The present invention provides novel IGF-I receptor subunits characterized by modified IGF-I receptor function, novel polynucleic acid sequences that encode these receptor subunits, and various applications for their use.

Abstract: Human Myt-1 kinase polypeptides and DNA (RNA) encoding such enzyme and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such human Myt-1 kinase in the development of treatments for cancers, such as leukemias, solid tumors and metastases; chronic inflammatory proliferative diseases, such as psoriasis and rheumatoid arthritis; proliferative cardiovascular diseases, such as restenosis; proliferative ocular disorders, such as diabetic retinopathy and macular degeneration; and benign hyperproliferative diseases, such as benign prostatic hypertrophy and hemangiomas, among others, are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides.

Abstract: HFGAN72Y polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing HFGAN72Y polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.

Abstract: Human G-protein coupled receptor polypeptides and DNA (RNA) encoding such polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such polypeptides for identifying antagonists and agonists to such polypeptides and methods of using the agonists and antagonists therapeutically to treat conditions related to the underexpression and overexpression of the G-protein coupled receptor polypeptides, respectively. Also disclosed are diagnostic methods for detecting a mutation in the G-protein coupled receptor nucleic acid sequences and an altered level of the soluble form of the receptors.

Abstract: Polypeptide of a growth factor receptor family, having a specific sequence and presenting all or part of the following properties: it encourages and/or is involved in the proliferation and/or differentiation of hematopoietic cell lines when obtained from the MPLV retrovirus; it is capable of acting as a hematopoietic growth factor receptor; it is recognized by antibodies directed against it. Polypeptides similar to the above. Applications in the diagnosis of the expression of said ligand polypeptide.

Abstract: Purified and isolated nucleic acid is provided which encodes a transferrin receptor protein of a strain of Haemophilus or a fragment or an analog of the transferrin receptor protein. The nucleic acid sequence may be used to produce peptides free of contaminants derived from bacteria normally containing the Tbp1 or Tbp2 proteins for purposes of diagnostics and medical treatment. Furthermore, the nucleic acid molecule may be used in the diagnosis of infection. Also provided are recombinant Tbp1 or Tbp2 and methods for purification of the same. Live vectors expressing epitopes of transferrin receptor protein for vaccination are provided.

Abstract: The present invention relates to TKA-1 polypeptides, nucleic acids encoding such polypeptides, cells, tissues and animals containing such nucleic acids, antibodies to such polypeptides, assays utilizing such polypeptides, and methods relating to all of the foregoing. Methods for treatment, diagnosis, and screening are provided for TKA-1 related diseases or conditions characterized by an abnormal interaction between a TKA-1 polypeptide and a TKA-1 binding partner.

Abstract: Disclosed are an isolated and purified protein acting as an angiogenic factor and nucleotide sequences encoding for such a protein, vectors containing such sequences and cells transformed by such vectors.

Abstract: A novel protein tyrosine kinase, JAK3, and a polynucleotide sequence encoding JAK3 polypeptide are disclosed herein. JAK3 is a new member of the JAK family of protein tyrosine kinases which are important in regulation of cellular proliferation and differentiation. Also disclosed are therapeutic methods utilizing JAK3 polypeptide and polynucleotide sequences.

Abstract: Lyophilized M-CSF formulations are presented that are free of high molecular weight species and stable to prolonged storage.

Abstract: The present invention relates to a complex comprising hepatocyte growth factor (HGF) and met proto-oncogene protein. The present invention also relates to methods for detecting the presence of HGF ligand, met proto-oncogene receptor and methods for isolating either the ligand or receptor or complex comprising both. The present invention further relates to methods of diagnostic proliferative disorders and diseases such as hepatitis or hepatocarcinogenesis by detecting these ligand-receptor pairs.

Abstract: The present invention relates to antibodies against an alpha interferon receptor, as well as to kits comprising such antibodies. The antibodies of the invention are suitable for the assay of the receptors or for their visualization in the case of imaging. The present antibodies and kits can thus be used as diagnostics or imaging agents, or as pharmacological models to test compounds derived from human alpha interferon.

Abstract: A recombinant non-glycosylated mammalian growth factor (BTC-GF) stimulates proliferation of human smooth muscle cells. Especially, the amino acid sequence of the protein deduced from the nucleotide sequence coding for human BTC-GF is as that comprising the amino acids No. 1 to No. 147 of FIG. 10 (SEQ ID NO:5) or the amino acids No. 1 to 80 of FIG. 10 (SEQ ID NO:18), and the amino acid sequence of the protein deduced from the nucleotide sequence coding for mouse BTC-GF is as that comprising the amino acids No. 1 to No. 146 of FIG. 9 (SEQ ID NO:17).

Abstract: The present invention provides two regulators of G-protein signaling (designated individually as RGPS-1 and RGPS-2, and collectively as RGPS) and polynucleotides which identify and encode RGPS. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention also provides methods for producing RGPS and for treating or preventing disorders associated with expression of RGPS.

Abstract: The invention provides isolated nucleic acids molecules, designated muscarinic acetylcholine receptor 6 ("mACHR-6") nucleic acid molecules, which encode polypeptides involved in the modulation of acetylcholine responses in acetylcholine responsive cells. The invention also provides antisense nucleic acid molecules, expression vectors containing mACHR-6 nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which an mACHR-6 gene has been introduced or disrupted. The invention still further provides isolated mACHR-6 polypeptides, fusion polypeptides, antigenic peptides, and anti-mACHR-6 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.